Literature DB >> 15855832

Psychopathology in first-episode schizophrenia and antibodies to Toxoplasma gondii.

S Bachmann1, J Schröder, C Bottmer, E F Torrey, R H Yolken.   

Abstract

OBJECTIVE: Environmental factors such as infectious agents may contribute to the psychopathology and aetiology of schizophrenia. Toxoplasma gondii (TG) is a candidate infectious agent as it is known to replicate within the human central nervous system and to alter behaviour in experimental animals.
METHOD: The relationship between antibodies to TG and psychopathological symptoms was examined in 34 first-episode patients with schizophrenia.
RESULTS: Results of regression analyses revealed that symptoms on admission, predictors of outcome, age and family history of psychiatric disease influenced the levels of antibodies to TG.
CONCLUSIONS: These results indicate that TG infections may play a role in the clinical manifestation of psychopathology in a subgroup of patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855832     DOI: 10.1159/000085349

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  13 in total

Review 1.  Psychosis: an autoimmune disease?

Authors:  Adam A J Al-Diwani; Thomas A Pollak; Sarosh R Irani; Belinda R Lennox
Journal:  Immunology       Date:  2017-08-03       Impact factor: 7.397

2.  In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin.

Authors:  Lorraine Jones-Brando; John D'Angelo; Gary H Posner; Robert Yolken
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  Fetomaternal and Pediatric Toxoplasmosis.

Authors:  Helieh S Oz
Journal:  J Pediatr Infect Dis       Date:  2017-12       Impact factor: 0.293

4.  Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis.

Authors:  Joel M Monroe; Peter F Buckley; Brian J Miller
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

5.  A controlled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence.

Authors:  Dunja Hinze-Selch; Walter Däubener; Lena Eggert; Sükran Erdag; Renate Stoltenberg; Sibylle Wilms
Journal:  Schizophr Bull       Date:  2007-03-26       Impact factor: 9.306

6.  Novel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal Toxoplasmosis.

Authors:  Helieh S Oz
Journal:  Int J Clin Med       Date:  2014-08

7.  Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Teshome Shibre; Atalay Alem; Abdulreshid Abdulahi; Mesfin Araya; Teferra Beyero; Girmay Medhin; Negusse Deyassa; Alemayehu Negash; Alemayehu Nigatu; Derege Kebede; Abebaw Fekadu
Journal:  Schizophr Bull       Date:  2009-02-04       Impact factor: 9.306

Review 8.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

9.  Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model.

Authors:  Helieh S Oz; Thomas Tobin
Journal:  Med Sci Monit       Date:  2012-09

10.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.